Hsbc Holdings PLC Acquires New Position in Medpace Holdings, Inc. $MEDP

Hsbc Holdings PLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,829 shares of the company’s stock, valued at approximately $2,164,000.

A number of other institutional investors have also bought and sold shares of MEDP. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace during the fourth quarter worth approximately $30,000. Elyxium Wealth LLC purchased a new stake in Medpace in the 4th quarter valued at $30,000. Quarry LP purchased a new stake in Medpace in the 3rd quarter valued at $35,000. Bayban acquired a new stake in shares of Medpace in the 4th quarter worth $44,000. Finally, Core Wealth Advisors LLC acquired a new stake in shares of Medpace in the 4th quarter worth $47,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Price Performance

Shares of MEDP opened at $534.72 on Tuesday. Medpace Holdings, Inc. has a 1-year low of $306.70 and a 1-year high of $628.92. The stock has a market cap of $15.27 billion, a PE ratio of 33.61, a P/E/G ratio of 2.67 and a beta of 1.18. The firm has a 50-day simple moving average of $451.57 and a two-hundred day simple moving average of $496.59.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the previous year, the company earned $3.67 earnings per share. The firm’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of several recent research reports. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. BMO Capital Markets cut their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Barclays decreased their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Finally, Royal Bank Of Canada dropped their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.